Long Term Safety Profile of the PRO-Kinetic ENERGY Coronary Stent System in Daily Clinical Practice
Launched by BIOTRONIK AG · Jan 25, 2010
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient signed informed consent for data release
- • Patient eligible for percutaneous coronary intervention (PCI)
- • De novo and re-stenosed coronary artery lesions
- • Patient is geographically stable and willing to participate at all follow up assessments
- • Patient is \> 18 years of age
- Exclusion Criteria:
- • Patient receives more than one stent, which is not a PRO-Kinetic ENERGY stent within the same vessel
- • Patient has a known allergy against aspirin, clopidogrel, ticlopidine, heparin or any other anticoagulation / antiplatelet therapy required for PCI
- • Patient presents with ISR (in-stent restenosis)
About Biotronik Ag
Biotronik AG is a leading global medical technology company, headquartered in Berlin, Germany, specializing in innovative cardiovascular and endovascular solutions. With a strong commitment to advancing patient care, Biotronik develops cutting-edge devices and therapies that enhance the diagnosis and treatment of cardiovascular diseases. The company's extensive portfolio includes implantable cardiac devices, vascular interventions, and remote patient monitoring systems, all designed to improve clinical outcomes and quality of life. Biotronik AG is dedicated to rigorous clinical research and collaboration with healthcare professionals, ensuring the highest standards of safety and efficacy in its products.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Haifa, , Israel
Rehovot, , Israel
Maastricht, , Netherlands
Amsterdam, , Netherlands
Haifa, , Israel
Zürich, , Switzerland
Amsterdam, , Netherlands
Lausanne, , Switzerland
Bonn, , Germany
Regensburg, , Germany
Almeria, , Spain
Pau, , France
Zefat, , Israel
Bad Oeynhausen, , Germany
Caceres, , Spain
Riga, , Latvia
Bruck An Der Mur, , Austria
Schwarzach St. Veit, , Austria
Brussels, , Belgium
Yvoir, , Belgium
Aix En Provence, , France
Avignon, , France
Bourg En Bresse, , France
Chartres, , France
Grenoble, , France
Marignane, , France
Perpignan, , France
Essen, Nrw, Germany
Berlin, , Germany
Berlin, , Germany
Dortmund, , Germany
Dresden, , Germany
Essen, , Germany
Essen, , Germany
Hamburg, , Germany
Lünen, , Germany
Osnabrück, , Germany
Speyer, , Germany
Stade, , Germany
Suhl, , Germany
Witten, , Germany
Craigavon, , Ireland
Beer Yakov, , Israel
Riga, , Latvia
Barcelona, , Spain
Barcelona, , Spain
Madrid, , Spain
Vigo, , Spain
Vizcaya, , Spain
Lausanne, , Switzerland
Patients applied
Trial Officials
Raimund Erbel, MD
Principal Investigator
Klinik für Kardiologie Westdeutsches Herzzentrum Essen, Universitätsklinikum Essen, Hufelandstrasse 55, D-45122 Essen, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials